• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nanobiotix S.A. - ADSs (NQ: NBTX )

    3.100 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 74
    Open 3.100
    Bid (Size) 2.100 (5)
    Ask (Size) 3.280 (77)
    Prev. Close 3.100
    Today's Range 3.100 - 3.100
    52wk Range 2.760 - 8.962
    Shares Outstanding 34,432,122
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
    From Nanobiotix S.A.
    Via GlobeNewswire
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire

    Performance

    YTD
    -57.79%
    -57.79%
    1 Month
    -18.17%
    -18.17%
    3 Month
    -37.12%
    -37.12%
    6 Month
    -28.90%
    -28.90%
    1 Year
    -53.52%
    -53.52%

    More News

    Read More
    Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
    From Nanobiotix S.A.
    Via GlobeNewswire
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX to Participate in Multiple Investor Conferences in November
    From Nanobiotix S.A.
    Via GlobeNewswire
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
    From Nanobiotix S.A.
    Via GlobeNewswire
    Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Nanobiotix S.A.
    Via GlobeNewswire
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
    From Nanobiotix S.A.
    Via GlobeNewswire
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
    From Nanobiotix S.A.
    Via GlobeNewswire
    Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
    From Nanobiotix S.A.
    Via GlobeNewswire
    Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
    From Nanobiotix S.A.
    Via GlobeNewswire
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
    From Nanobiotix S.A.
    Via GlobeNewswire
    NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
    From Nanobiotix S.A.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.